A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

2019 | JOURNAL DOI: 10.1080/15384047.2018.1523095

Want to explore more research activities?

See how Impactio can help you with your research career.

Start